The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $61.05

Today's change-0.37 -0.60%
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $61.05

Today's change-0.37 -0.60%
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd down (U.S.)$0.37

Teva Pharmaceutical Industries Ltd closed lower Friday, dropping (U.S.)$0.37 or 0.60% to (U.S.)$61.05. Over the last five days, shares have gained 1.36% and 6.16% year to date. Shares have outperformed the S&P 500 by 8.17% during the last year.

Key company metrics

  • Open(U.S.) $61.28
  • Previous close(U.S.) $61.42
  • High(U.S.) $61.83
  • Low(U.S.) $60.78
  • Bid / Ask-- / --
  • YTD % change+6.16%
  • Volume2,906,501
  • Average volume (10-day)3,689,408
  • Average volume (1-month)4,782,352
  • Average volume (3-month)5,655,621
  • 52-week range(U.S.) $47.36 to (U.S.) $68.75
  • Beta0.57
  • Trailing P/E19.00×
  • P/E 1 year forward11.61×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $1.35
  • Dividend yield2.20%
  • Trailing EPS(U.S.) $3.21
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+13.59%

Based on its net profit margin of 13.59%, Teva Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.02%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue4,9825,1685,0585,045
Total other revenue--------
Total revenue4,9825,1685,0585,045
Gross profit2,8362,8892,8092,661
Total cost of revenue2,1462,2792,2492,384
Total operating expense4,2334,2263,9464,120
Selling / general / administrative1,2211,3261,2401,211
Research & development332379412344
Depreciation / amortization8--37
Interest expense (income), net operating--------
Unusual expense (income)52624242169
Other operating expenses, total--------
Operating income7499421,112925
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax5578721,028847
Income after tax453686868745
Income tax, total104186160102
Net income446687876748
Total adjustments to net income----0--
Net income before extra. items446687876748
Minority interest2-7133
Equity in affiliates-98-5--
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items446687876748
Inc. avail. to common incl. extra. items446687876748
Diluted net income447689878748
Dilution adjustment1220
Diluted weighted average shares859861861857
Diluted EPS excluding extraordinary itemsvalue per share0.520.801.020.87
Dividends per sharevalue per share0.350.320.340.35
Diluted normalized EPSvalue per share1.021.021.061.05